GALETTA, DIANA URANIA
 Distribuzione geografica
Continente #
NA - Nord America 118
AS - Asia 94
EU - Europa 79
SA - Sud America 41
AF - Africa 4
Totale 336
Nazione #
US - Stati Uniti d'America 111
SG - Singapore 48
IT - Italia 36
BR - Brasile 34
IE - Irlanda 23
HK - Hong Kong 14
VN - Vietnam 14
CN - Cina 12
RU - Federazione Russa 9
CA - Canada 6
DE - Germania 4
AR - Argentina 3
BD - Bangladesh 2
EC - Ecuador 2
GB - Regno Unito 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
EG - Egitto 1
ES - Italia 1
ID - Indonesia 1
JP - Giappone 1
KE - Kenya 1
KZ - Kazakistan 1
MX - Messico 1
NL - Olanda 1
PE - Perù 1
PL - Polonia 1
PT - Portogallo 1
PY - Paraguay 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 336
Città #
Singapore 32
Dublin 23
Chandler 22
Perugia 19
Hong Kong 14
Dallas 9
Altamura 6
Ashburn 6
Boardman 6
Bologna 6
Ho Chi Minh City 6
New York 6
Lawrence 4
Medford 4
Moscow 4
Princeton 4
Santa Clara 4
São Paulo 4
Rome 3
Beijing 2
Chicago 2
Columbus 2
Hanoi 2
Los Angeles 2
Montreal 2
Nuremberg 2
Piracicaba 2
San Mateo 2
San Paolo di Civitate 2
Serrinha 2
Almaty Oblysy 1
Americana 1
Amparo 1
Amsterdam 1
Asunción 1
Avellaneda 1
Bady Bassitt 1
Barreiras 1
Biên Hòa 1
Boston 1
Buenos Aires 1
Bắc Ninh 1
Cairo 1
Calgary 1
Campo Formoso Municipality 1
Capivari 1
Catanduva 1
Conceição de Macabu 1
Contagem 1
Crystal Lake 1
Cuiabá 1
Falkenstein 1
Garopaba 1
Guangzhou 1
Guayaquil 1
Gurupi 1
Hải Dương 1
Itapecerica da Serra 1
Johannesburg 1
Lima 1
Lisbon 1
Luziânia 1
Makassar 1
Miguel Alves 1
Milwaukee 1
Munich 1
Nairobi 1
Nova Iguaçu 1
Ottawa 1
Pskov 1
Querétaro 1
Quito 1
Quận Bình Thạnh 1
Quận Phú Nhuận 1
Redmond 1
Resistencia 1
Rio de Janeiro 1
Rondonópolis 1
Saint Petersburg 1
Santos 1
Sobral 1
São Bernardo do Campo 1
São José do Belmonte 1
São José dos Campos 1
São Sebastião 1
Tangshan 1
The Dalles 1
Tokyo 1
Tunis 1
Ubá 1
Várzea Paulista 1
Vĩnh Tường 1
Warsaw 1
Wilmington 1
Totale 268
Nome #
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 102
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 93
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 78
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 74
Totale 347
Categoria #
all - tutte 1.503
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.503


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 1 0 0
2021/202217 0 2 0 0 0 0 0 10 0 0 1 4
2022/202375 4 17 1 6 5 6 0 3 31 1 1 0
2023/202421 0 5 1 1 0 0 6 0 0 1 2 5
2024/202592 0 4 0 10 9 1 7 29 10 3 12 7
2025/2026134 11 26 23 44 26 4 0 0 0 0 0 0
Totale 347